Compounded Tirzepatide: What It Is, Dosage and How It Works
September 29, 2026
Liv Health editorial team
3 min read
Key Takeaways
Tirzepatide acts on two appetite signals, GIP and GLP-1, and may
help reduce hunger and cravings.
It may help you lose weight as part of a provider-guided plan.
A compounded prescription is prepared by a licensed pharmacy for
you, to the prescription your provider writes.
Your provider reviews your health history and required labs before
deciding what to prescribe.
Before each refill, your provider reviews how you're doing and
adjusts your plan as needed.
When hunger keeps getting in the way, willpower isn't the whole
story. Many US adults living with obesity say controlling hunger
is a barrier to starting a weight-loss effort. Appetite is driven by
signals your body sends, and tirzepatide works on those signals.
How Can Tirzepatide Help
With Hunger?
Tirzepatide activates two hormone receptors involved in appetite, GIP
and GLP-1. The Zepbound
prescribing information describes GLP-1 as a natural regulator of
appetite and calorie intake, with receptors in the areas of the brain
that manage it.
Tell your provider what hits hardest, whether that's hunger between
meals, cravings for sweets or rich foods, or something else. Your plan
can be built around it.
What Results Can Look Like
On average, people who stayed on approved tirzepatide injections kept
losing weight through their first year. In a large real-world study,
people still on treatment lost an average of 5.9%
of their starting weight at 3 months, 10.1% at 6 months and 15.3% at 12
months. Results differ from person to person, so you and your
provider review your progress as you go.
What Does a Compounded
Prescription Mean?
It means your medicine is made for you. A licensed compounding
pharmacy prepares it to the prescription your provider writes, rather
than a manufacturer making it for everyone. Our guide to compounded
medicines explains more.
Compounded tirzepatide: Medicine containing
tirzepatide, prepared by a licensed compounding pharmacy for one
patient's prescription.
Zepbound: An FDA-approved tirzepatide product with
its own prescribing information.
Liv offers both. Your provider reviews which option fits your health
history and goals, and your prescription tells you exactly which
medicine you're using and how to use it.
How Your Provider Builds
Your Plan
Your plan starts with an evaluation. A licensed provider reviews your
health history, the medicines you take and your required labs, then
decides whether tirzepatide is right for you.
If it is, your provider chooses your dose and schedule. Follow the
instructions supplied with your medicine, and ask your provider or
pharmacist about anything that's unclear. For a compounded vial, the
amount you draw into a syringe depends on that vial's concentration, so
always go by your own prescription.
The most common side effects listed
on the Zepbound label are stomach-related: nausea, diarrhea,
vomiting, constipation, abdominal pain and indigestion.
Tirzepatide isn't right for everyone. Your provider will ask
about:
Thyroid history: a personal or family history of
medullary thyroid cancer or MEN 2.
Past conditions: pancreatitis, gallbladder disease
or kidney problems.
Other medicines: especially diabetes medicines that
can lower blood sugar.
Allergies: any serious allergic reaction to a
medicine.
Contact your provider promptly about severe or lasting stomach pain,
ongoing vomiting or signs of dehydration.
What Happens as Your Plan
Continues?
Before each refill, you tell Liv how you're doing, and your provider
reviews that update along with your plan. Bring up changes in appetite,
any side effects and anything that's hard about the routine. Ask before
changing your dose or schedule, so every adjustment fits your
progress.
Start with what you want help with, and bring your questions about
hunger, the medicine and the routine. Your provider will walk you
through the options and how your progress will be reviewed.
An evaluation is the next step in
discussing whether compounded tirzepatide, Zepbound or another option is
right for you.
The study didn't test a compounded preparation, and results vary from person to person, so your provider will check in on how you're doing.
Where do the weight-loss figures come from?
They come from a real-world observational study of 18,386 matched adults receiving an approved tirzepatide or semaglutide injection (Rodriguez et al., JAMA Internal Medicine, 2024). Of those adults, 52% had type 2 diabetes.
The figures describe people still on treatment, and each timepoint is a separate estimate, so they shouldn't be added together. The tirzepatide injection in that study is approved for type 2 diabetes, so its use for weight management was off-label, and the results concern approved injections, not a compounded preparation.
Individual results vary. Doses weren't verified, more than half of people stopped treatment during follow-up (52.5% of those on semaglutide and 55.9% on tirzepatide), and missing weights were estimated statistically.
Is compounded tirzepatide the same as Zepbound?
They contain the same active ingredient, but they're different products. Zepbound is FDA-approved. A compounded preparation is made by a licensed pharmacy for one patient's prescription, and it isn't a generic version of Zepbound.
Zepbound is approved for adults living with obesity, and adults who are overweight and have at least one weight-related health condition, to reduce excess weight and keep it off long term.
Zepbound is also approved to treat moderate to severe obstructive sleep apnea in adults living with obesity. Both uses pair it with a reduced-calorie diet and more physical activity.
Can you take compounded tirzepatide and Zepbound together?
No. The Zepbound label advises against it. Taking Zepbound with other medicines that contain tirzepatide, or with any medicine that acts on the GLP-1 receptor, such as semaglutide, isn't recommended. Share your full medicine list with your provider before you start.
How often do you take tirzepatide?
Approved tirzepatide is taken once a week. Its label says any time of day works, with or without meals. For compounded tirzepatide, your prescription sets the schedule.
Why does tirzepatide start at a lower dose?
To help lower the risk of stomach side effects. On the Zepbound label, the dose begins low and increases in steps.
When choosing the ongoing dose, the label asks prescribers to weigh how well it's working and how well it's tolerated. For compounded tirzepatide, your provider sets your dose and decides when it changes.
What does the boxed warning on Zepbound say?
The Zepbound label carries a boxed warning about thyroid C-cell tumors. Tirzepatide caused these tumors in rats; it isn't known whether it does in people. Zepbound isn't for anyone with a personal or family history of medullary thyroid cancer or MEN 2, or a serious allergy to tirzepatide.
Nausea is the most common side effect listed on the Zepbound label. The label also says Zepbound isn't recommended for severe gastroparesis, and to tell your care team before any procedure with anesthesia or deep sedation.
The Zepbound label notes that routine blood tests (calcitonin) or thyroid ultrasound are of uncertain value for catching these tumors early, so tell your provider about a lump in your neck, trouble swallowing, shortness of breath or hoarseness that doesn't go away.
Will my prescription tell me how much to take?
Yes. Follow the dose and instructions supplied for your medicine. If you're unsure about the vial concentration, syringe markings or schedule, ask your provider or pharmacist before using it.
Why is tirzepatide compared with semaglutide?
Both act on the GLP-1 receptor, which is involved in appetite. Tirzepatide also acts on the GIP receptor. Your history and goals guide the choice with your provider.
References
Kaplan, L. M., Golden, A., Jinnett, K., Kolotkin, R. L., Kyle, T. K., Look, M., et al. (2018). Perceptions of barriers to effective obesity care: Results from the National ACTION Study. Obesity, 26(1), 61-69. https://pubmed.ncbi.nlm.nih.gov/29086529/
Tirzepatide on ingestive behavior in adults with overweight or obesity: A randomized 6-week phase 1 trial. (2025). Nature Medicine. doi:10.1038/s41591-025-03774-9. Read September 11, 2026. https://www.nature.com/articles/s41591-025-03774-9